» Articles » PMID: 26449949

Invasive Nontyphoidal Salmonella Infections Among Children in Mali, 2002-2014: Microbiological and Epidemiologic Features Guide Vaccine Development

Abstract

Background: In 2002, following establishment of a clinical microbiology laboratory in the government hospital that admits children with severe illnesses in Bamako, Mali, surveillance to identify pathogens causing invasive bacterial infections (septicemia, bacteremia, meningitis, etc) was initiated.

Methods: Parents/guardians of children aged <16 years admitted to l'Hôpital Gabriel Touré with high fever or clinical syndromes compatible with focal invasive bacterial disease were asked for consent to culture their child's blood/body fluid. Standard bacteriologic techniques speciated isolates; Salmonella serovars were determined.

Results: From July 2002 through June 2014, 687 nontyphoidal Salmonella (NTS) isolates were obtained from 667 children; 667 yielded a single serovar and 20 grew 2 Salmonella serovars, 1 being NTS. Four serovars accounted for 87% of the 687 NTS isolates, including Salmonella Enteritidis (n = 244 [35.5%]), Salmonella Typhimurium (n = 221 [32.2%]), I:4,[5],12:i:- (n = 42 [6.1%]), and Salmonella Dublin (n = 89 [13.0%]). Of 553 patients with invasive NTS from whom 1 of the 4 predominant serovars was isolated in pure culture, 448 (81.0%) were aged <5 years and case fatality was 20.3%; Salmonella Enteritidis case fatality (27.8%) was higher than for other serovars (P = .0009). NTS disease showed a seasonal peak following the rainy season and into the cool, dry season. Since 2010, Salmonella Enteritidis cases have risen and Salmonella Typhimurium fallen.

Conclusions: NTS has become the predominant invasive pathogen as Haemophilus influenzae type b and pneumococcal vaccine use in Mali has diminished invasive disease due to those pathogens. The age distribution and limited serovars involved make control of NTS disease by vaccines epidemiologically feasible, if products under development prove safe and efficacious.

Citing Articles

Deletion of an immune evasion gene, , from a live serovar Typhimurium vaccine improves vaccine responses in aged mice.

Allen J, Natta S, Nasrin S, Toapanta F, Tennant S Front Immunol. 2024; 15:1376734.

PMID: 38911854 PMC: 11190192. DOI: 10.3389/fimmu.2024.1376734.


Evaluation of Three Candidate Live-Attenuated Serovar Typhimurium Vaccines to Prevent Non-Typhoidal Infection in an Infant Mouse Model.

Sears K, Nasrin S, Baliban S, Council D, Pasetti M, Tennant S Vaccines (Basel). 2023; 11(10).

PMID: 37896965 PMC: 10610874. DOI: 10.3390/vaccines11101562.


Prevalence of Salmonella in Stool During the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018.

Kasumba I, Powell H, Omore R, Hossain M, Sow S, Ochieng J Clin Infect Dis. 2023; 76(76 Suppl1):S87-S96.

PMID: 37074429 PMC: 10116559. DOI: 10.1093/cid/ciac985.


Case-control investigation of invasive Salmonella disease in Malawi reveals no evidence of environmental or animal transmission of invasive strains, and supports human to human transmission.

Koolman L, Prakash R, Diness Y, Msefula C, Nyirenda T, Olgemoeller F PLoS Negl Trop Dis. 2022; 16(12):e0010982.

PMID: 36508466 PMC: 9779717. DOI: 10.1371/journal.pntd.0010982.


Evaluation of Typhimurium Lacking , , or as a Prophylactic Vaccine against Lethal Infection.

Park S, Jung B, Kim E, Yoon H, Hahn T Vaccines (Basel). 2022; 10(9).

PMID: 36146494 PMC: 9506222. DOI: 10.3390/vaccines10091413.


References
1.
Kariuki S, Revathi G, Kariuki N, Kiiru J, Mwituria J, A Hart C . Characterisation of community acquired non-typhoidal Salmonella from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya. BMC Microbiol. 2006; 6:101. PMC: 1764016. DOI: 10.1186/1471-2180-6-101. View

2.
Enwere G, Biney E, Cheung Y, Zaman S, Okoko B, Oluwalana C . Epidemiologic and clinical characteristics of community-acquired invasive bacterial infections in children aged 2-29 months in The Gambia. Pediatr Infect Dis J. 2006; 25(8):700-5. DOI: 10.1097/01.inf.0000226839.30925.a5. View

3.
Mandomando I, Macete E, Sigauque B, Morais L, Quinto L, Sacarlal J . Invasive non-typhoidal Salmonella in Mozambican children. Trop Med Int Health. 2009; 14(12):1467-74. DOI: 10.1111/j.1365-3156.2009.02399.x. View

4.
Tennant S, Diallo S, Levy H, Livio S, Sow S, Tapia M . Identification by PCR of non-typhoidal Salmonella enterica serovars associated with invasive infections among febrile patients in Mali. PLoS Negl Trop Dis. 2010; 4(3):e621. PMC: 2834738. DOI: 10.1371/journal.pntd.0000621. View

5.
Simon R, Tennant S, Wang J, Schmidlein P, Lees A, Ernst R . Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis. Infect Immun. 2011; 79(10):4240-9. PMC: 3187246. DOI: 10.1128/IAI.05484-11. View